DEWIZ
21.6.2021 15:36:09 CEST | Business Wire | Press release
After more than five years of development, deWiz’s new wearable technology is going to market after closing out its Series-A funding round with more than 5M USD in new investment. The funding will fuel deWiz’s go-to-market launch strategy with a robust marketing plan, staffing to support growth and resources to ensure a healthy supply chain. Additionally, investment was synced with a new composition of the board of directors for deWiz, including Chairman of the Board, CEO and co-founder Christian Bergh; CTO and co-founder Markus Westerberg; World Golf Hall of Fame and business entrepreneur Annika Sörenstam; Newton Aguiar; and Erik Näsström.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210621005497/en/
The science behind deWiz minimizes the guesswork of improving your golf swing and allows golfers to simply “swing, feel and improve faster.” Described by Forbes as looking to bring a “jolt to the golf training aid market ,” deWiz’s innovative technology merges high-precision swing analysis with its revolutionary Learning Stimuli, which provides real-time haptic feedback with a buzz on the golfer’s wrist and/or an audio alert the moment a golfer’s swing goes astray. The magic of this instantaneous feedback is scientifically based on motor learning, which allows golfers using deWiz to more quickly adjust their golf swing motion and accelerate their learning process.
“deWiz’s data capture capabilities are unmatched via our wearable device, precisely measuring golf swing data like transition plane, length of backswing, hand speed and tempo ratio like never before. But what sets deWiz apart is our Learning Stimuli, which minimizes the guesswork. Other swing analysis tools require interpreting data on a screen and translating that into a proper swing, which is a time-consuming, trial-and-error process. Meanwhile, deWiz combines its high-precision data with real-time feedback within a golfer’s swing to help them improve faster,” said Markus Westerberg, co-founder and CTO of deWiz and certified PGA of Sweden instructor.
DEVELOPED BY EXPERTS, TESTED BY PROS: deWiz’s innovative technology has attracted an impressive roster of global ambassadors. The product has been in development for more than five years and tested by a range of champions, including 2020 U.S. Open Champion Bryson DeChambeau, 10-time Major Champion Annika Sorenstam, 3-time Major Champion Vijay Singh, 2-time Major Champion Lydia Ko, 2016 Open Champion Henrik Stenson, 2019 Houston Open Champion Lanto Griffin and 2-time World Long Drive Champion Tim Burke.
SWING, FEEL, IMPROVE: deWiz’s user-friendly app and wearable tech tracks the precise position of a golfer’s hands throughout their swing, providing a 3D analysis. This innovative approach to golf instruction is backed by patented technology, which deWiz currently has secured with 7 patent families that have been granted or are pending across the U.S., Europe, and other strategic global markets.
Within the app, current swing training features include Transition , Length of Backswing , Wedge Distance and Tempo . These unique deWiz data points help any avid golfer, teaching professional or world-class player can better know their numbers to efficiently refine a consistent swing.
Currently for sale for 699 USD and available across the United States, Europe, and South Korea (more markets opening regularly – visit the website for the latest updates), deWiz is offering an introductory, limited-time discount of 10% off to celebrate this wearable technology’s buzzworthy launch. Please visit www.dewizgolf.com for more details on how to improve your swing faster or download the app to explore its features via Apple’s App Store or Google Play.
ABOUT deWiz
The deWiz golf training platform has been developed by former European Tour pro, PGA of Sweden certified instructor and motor learning author, Markus Westerberg, and entrepreneur and technology business leader Christian Berg. deWiz is a Swedish developed and produced product and is driven by its mission to help golfers around the world elevate their enjoyment of the game through innovative technology that accelerates the pace of learning. deWiz’s revolutionary wearable technology delivers groundbreaking instantaneous feedback that is based on a scientific approach of breaking cycles within motor learning and propelling golfers to improve faster.
Imagery Available Here – For Media Purposes Only
View source version on businesswire.com: https://www.businesswire.com/news/home/20210621005497/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release
The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
